Diabetes Market Analysis, Size, Trends | 2019-2025 | MedSuite
- Year: 2019
- Scope: 2015-2025
- Region: Europe, United States
- Published Date: 06/04/2019
- Pages: 754
- Type: MedSuite
The fastest-growing segment in the U.S. diabetes market is the FGM market, which has increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM. Abbott received FDA approval for FreeStyle® Libre and for FreeStyle® Libre 14 Day. The FGM market has experienced significant growth in international markets since it was first commercially launched in Europe almost ten years ago. Growth in the U.S. market is expected to follow a similar trend, primarily attributed to an expanding installed base of FGM users.
In the EU diabetes market, pricing pressure and price erosion are common occurrences, as new competitors enter the blood glucose monitoring market and pen needle markets, with low-price strategies and products. The presence of these new competitors puts downward pressure on the average selling price and has caused traditional market leaders to introduce low-priced products of their own, in order to counteract the increased competition in the segment. Tender negotiations and budgetary pressures on national healthcare expenditure also contribute to the decline in prices and have resulted in market value contractions in certain regions. It is expected that the trend of pricing pressure will continue throughout the forecast period, limiting the value of the blood glucose monitoring and the pen needle markets.
Report Regional Coverage
Throughout this research series, iData has covered several countries in great detail. Each country may be purchased as a stand-alone report, tailoring the data to your needs. The covered countries are:
- United States
- Europe (15 countries including: Germany, France, U.K., Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Denmark, Finland, Norway and Sweden) Austria, Switzerland and Portugal)
The Only Medical Device Market Research With:
|✔ Unit Sales Growth Analysis
✔ Average Selling Prices
✔ Competitor Shares by Segment & Country
✔ SKU-Level Research Methods
✔ The Lowest Acquisition Cost
Highly Detailed Segmentation
While this report suite contains all U.S. diabetes device data, each of the markets are also available as stand alone MedCore reports. This allows you to get access to only the diabetes device market research that you need. You can view all these included reports and segmentation here:
- Diabetes Monitoring, Treatment and Drug Delivery – MedPro
- Blood Glucose Meters – MedCore
- Blood Glucose Test Strips – MedCore
- Lancet and Lancing Devices – MedCore
- Continuous Glucose Monitoring – MedCore
- Insulin – MedCore
- Insulin Pen – MedCore
- Insulin Syringes – MedCore
- Insulin Pumps – MedCore
Buying all of these reports together in this suite package will provide you with substantial discounts from the separate prices. Request Pricing to Learn More
Full Segmentation Map for the United States
Data Types Included
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2025, and Historical Data
- Market Drivers & Limiters for Each Diabetes Device Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Related Press Releases from Top Competitors
Diabetes Market Share Insights
In both the U.S. and EU markets, the vast majority of the overall market share was held by insulin manufacturers, Novo Nordisk, Eli Lilly and Sanofi. Novo Nordisk held the leading position in the ultra-long-acting insulin rapid-acting insulin markets and the second-leading position in the long-acting insulin, premixed insulin and human insulin markets. Medtronic maintained its dominant position in the insulin pump market but has recently faced increased competition from Tandem’s t:slim X2™, as well as Dexcom’s G6® in the CGM market.
Other leading notable competitors in the market include Roche, Abbott and Becton Dickinson. Roche continued to hold the leading position in the blood glucose meter, blood glucose test strip and lancet markets, as well as the second-leading position in the insulin pump market. Abbott continued to benefit from its monopolistic position in the FGM market. Becton Dickinson remained dominant in the insulin pen needle and insulin syringe markets.
All Companies Analyzed in this Study
Statistics and Procedure Trends
Obesity is considered by leading health organizations, such as the Centers for Disease Control (CDC), as a prevalent disease both globally and in the United States. According to the CDC, there has been a considerable increase in the incidence of obesity in the U.S. over the past 20 years. The latest data on obesity in the U.S. shows that today, nearly 38% of adults at the age of 20 years and over are obese. For adolescents at the age of 12 to 19 years, children at the age of 6 to 11 years, and children at the age of 2 to 5 years, the obesity rate is considerably lower at approximately 21%, 17% and 9%, respectively. On the bright side, this rate has plateaued in the last few years. Being obese makes it difficult for cells to respond to insulin, thus the body reacts by releasing more insulin. Therefore, obesity has been seen as one of the main reasons behind the advance of type 2 diabetes among Americans.
Latest Market Developments
May 2019 – LifeScan enters into agreement with Sanvita Medical to market and distribute CGM devices
January 2019 – Ascensia Diabetes Care announces global partnership with POCTech to distribute and co-develop CGM systems
January 2019 – CGM pledge for pregnant woman with type 1 diabetes outlined in NHS plan
November 2018 – Dexcom and Verily amend collaboration and license agreement
November 2018 – NHS to provide increased access to FGM for type 1 diabetes patients
iData’s 9-Step Research MethodologyOur reports follow an in-depth 9-step methodology which focuses on the following research systems:
- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.